HEADER APOPTOSIS/INHIBITOR 16-JUL-14 4QVX TITLE DISCOVERY OF A POTENT AND SELECTIVE BCL-XL INHIBITOR THAT DEMONSTRATES TITLE 2 THROMBOCYTOPENIA AND INHIBITS TUMOR GROWTH IN VIVO COMPND MOL_ID: 1; COMPND 2 MOLECULE: BCL-2-LIKE PROTEIN 1; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: SEE REMARK 999; COMPND 5 SYNONYM: BCL2-L-1, APOPTOSIS REGULATOR BCL-X; COMPND 6 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: BCL2L1, BCL2L, BCLX; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS 8 ALPHA HELICES, ANTI-APOPTOTIC, PRO-APOPTOTIC, APOPTOSIS-INHIBITOR KEYWDS 2 COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR C.H.PARK REVDAT 3 28-FEB-24 4QVX 1 REMARK SEQADV REVDAT 2 26-JUL-17 4QVX 1 SOURCE REMARK REVDAT 1 22-JUL-15 4QVX 0 JRNL AUTH Z.F.TAO,L.HASVOLD,L.WANG,X.WANG,A.M.PETROS,C.H.PARK, JRNL AUTH 2 E.R.BOGHAERT,N.D.CATRON,J.CHEN,P.M.COLMAN,P.E.CZABOTAR, JRNL AUTH 3 K.DESHAYES,W.J.FAIRBROTHER,J.A.FLYGARE,S.G.HYMOWITZ,S.JIN, JRNL AUTH 4 R.A.JUDGE,M.F.KOEHLER,P.J.KOVAR,G.LESSENE,M.J.MITTEN, JRNL AUTH 5 C.O.NDUBAKU,P.NIMMER,H.E.PURKEY,A.OLEKSIJEW,D.C.PHILLIPS, JRNL AUTH 6 B.E.SLEEBS,B.J.SMITH,M.L.SMITH,S.K.TAHIR,K.G.WATSON,Y.XIAO, JRNL AUTH 7 J.XUE,H.ZHANG,K.ZOBEL,S.H.ROSENBERG,C.TSE,J.D.LEVERSON, JRNL AUTH 8 S.W.ELMORE,A.J.SOUERS JRNL TITL DISCOVERY OF A POTENT AND SELECTIVE BCL-XL INHIBITOR WITH IN JRNL TITL 2 VIVO ACTIVITY. JRNL REF ACS MED.CHEM.LETT. V. 5 1088 2014 JRNL REFN ISSN 1948-5875 JRNL PMID 25313317 JRNL DOI 10.1021/ML5001867 REMARK 2 REMARK 2 RESOLUTION. 2.10 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : BUSTER-TNT 2.5.1 REMARK 3 AUTHORS : BRICOGNE,BLANC,BRANDL,FLENSBURG,KELLER, REMARK 3 : PACIOREK,ROVERSI,SMART,VONRHEIN,WOMACK, REMARK 3 : MATTHEWS,TEN EYCK,TRONRUD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.10 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 56.98 REMARK 3 DATA CUTOFF (SIGMA(F)) : 1.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 99.8 REMARK 3 NUMBER OF REFLECTIONS : 16571 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.194 REMARK 3 R VALUE (WORKING SET) : 0.191 REMARK 3 FREE R VALUE : 0.257 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.050 REMARK 3 FREE R VALUE TEST SET COUNT : 837 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 9 REMARK 3 BIN RESOLUTION RANGE HIGH (ANGSTROMS) : 2.10 REMARK 3 BIN RESOLUTION RANGE LOW (ANGSTROMS) : 2.23 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 99.76 REMARK 3 REFLECTIONS IN BIN (WORKING + TEST SET) : 2619 REMARK 3 BIN R VALUE (WORKING + TEST SET) : 0.2060 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 2499 REMARK 3 BIN R VALUE (WORKING SET) : 0.2036 REMARK 3 BIN FREE R VALUE : 0.2529 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 4.58 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 120 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2186 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 94 REMARK 3 SOLVENT ATOMS : 153 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 31.26 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 33.38 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 4.75142 REMARK 3 B22 (A**2) : -1.53655 REMARK 3 B33 (A**2) : -3.21487 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 DPI (BLOW EQ-10) BASED ON R VALUE (A) : NULL REMARK 3 DPI (BLOW EQ-9) BASED ON FREE R VALUE (A) : NULL REMARK 3 DPI (CRUICKSHANK) BASED ON R VALUE (A) : NULL REMARK 3 DPI (CRUICKSHANK) BASED ON FREE R VALUE (A) : NULL REMARK 3 REMARK 3 REFERENCES: BLOW, D. (2002) ACTA CRYST D58, 792-797 REMARK 3 CRUICKSHANK, D.W.J. (1999) ACTA CRYST D55, 583-601 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : NULL REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : NULL REMARK 3 REMARK 3 NUMBER OF GEOMETRIC FUNCTION TERMS DEFINED : 15 REMARK 3 TERM COUNT WEIGHT FUNCTION. REMARK 3 BOND LENGTHS : NULL ; NULL ; NULL REMARK 3 BOND ANGLES : NULL ; NULL ; NULL REMARK 3 TORSION ANGLES : NULL ; NULL ; NULL REMARK 3 TRIGONAL CARBON PLANES : NULL ; NULL ; NULL REMARK 3 GENERAL PLANES : NULL ; NULL ; NULL REMARK 3 ISOTROPIC THERMAL FACTORS : NULL ; NULL ; NULL REMARK 3 BAD NON-BONDED CONTACTS : NULL ; NULL ; NULL REMARK 3 IMPROPER TORSIONS : NULL ; NULL ; NULL REMARK 3 PSEUDOROTATION ANGLES : NULL ; NULL ; NULL REMARK 3 CHIRAL IMPROPER TORSION : NULL ; NULL ; NULL REMARK 3 SUM OF OCCUPANCIES : NULL ; NULL ; NULL REMARK 3 UTILITY DISTANCES : NULL ; NULL ; NULL REMARK 3 UTILITY ANGLES : NULL ; NULL ; NULL REMARK 3 UTILITY TORSION : NULL ; NULL ; NULL REMARK 3 IDEAL-DIST CONTACT TERM : NULL ; NULL ; NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : NULL REMARK 3 BOND ANGLES (DEGREES) : NULL REMARK 3 PEPTIDE OMEGA TORSION ANGLES (DEGREES) : NULL REMARK 3 OTHER TORSION ANGLES (DEGREES) : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 4QVX COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 29-JUL-14. REMARK 100 THE DEPOSITION ID IS D_1000086580. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 16-DEC-10 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 8.0 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 17-ID REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.0 REMARK 200 MONOCHROMATOR : SI(111) REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 210 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : PROCESS REMARK 200 DATA SCALING SOFTWARE : PROCESS REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 16571 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.100 REMARK 200 RESOLUTION RANGE LOW (A) : 56.980 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 1.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.8 REMARK 200 DATA REDUNDANCY : NULL REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.10 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.23 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.8 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: MOLREP REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 33.94 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 1.86 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 10.73 UM COMPOUND IN DMSO + 2.14 UM REMARK 280 PROTEIN IN 25 MM TRIS, 0.1 M SODIUM CHLORIDE, 10% V/V GLYCEROL, REMARK 280 1 MM DTT, PH 8.0 INCUBATED OVERNIGHT AT 277K THEN CONCENTRATED REMARK 280 TO 12 MG/ML, 1:1 PROTEIN SOLUTION:RESERVOIR SOLUTION (3 M SODIUM REMARK 280 CHLORIDE, 0.1 M CITRIC ACID, PH 3.5) USED IN DROP, VAPOR REMARK 280 DIFFUSION, SITTING DROP, TEMPERATURE 290K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 2 2 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,-Y,Z+1/2 REMARK 290 3555 -X,Y,-Z+1/2 REMARK 290 4555 X,-Y,-Z REMARK 290 5555 X+1/2,Y+1/2,Z REMARK 290 6555 -X+1/2,-Y+1/2,Z+1/2 REMARK 290 7555 -X+1/2,Y+1/2,-Z+1/2 REMARK 290 8555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 41.86800 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 41.86800 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 5 1.000000 0.000000 0.000000 36.55350 REMARK 290 SMTRY2 5 0.000000 1.000000 0.000000 45.47750 REMARK 290 SMTRY3 5 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 6 -1.000000 0.000000 0.000000 36.55350 REMARK 290 SMTRY2 6 0.000000 -1.000000 0.000000 45.47750 REMARK 290 SMTRY3 6 0.000000 0.000000 1.000000 41.86800 REMARK 290 SMTRY1 7 -1.000000 0.000000 0.000000 36.55350 REMARK 290 SMTRY2 7 0.000000 1.000000 0.000000 45.47750 REMARK 290 SMTRY3 7 0.000000 0.000000 -1.000000 41.86800 REMARK 290 SMTRY1 8 1.000000 0.000000 0.000000 36.55350 REMARK 290 SMTRY2 8 0.000000 -1.000000 0.000000 45.47750 REMARK 290 SMTRY3 8 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2, 3 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 3 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A 1 REMARK 465 SER A 73 REMARK 465 ALA A 74 REMARK 465 SER A 75 REMARK 465 GLY A 76 REMARK 465 GLY A 77 REMARK 465 GLY A 78 REMARK 465 GLY A 79 REMARK 465 GLY A 80 REMARK 465 GLY A 81 REMARK 465 ASN A 197 REMARK 465 ASN A 198 REMARK 465 ALA A 199 REMARK 465 ALA A 200 REMARK 465 ALA A 201 REMARK 465 GLU A 202 REMARK 465 SER A 203 REMARK 465 ARG A 204 REMARK 465 LYS A 205 REMARK 465 GLY A 206 REMARK 465 GLN A 207 REMARK 465 GLU A 208 REMARK 465 ARG A 209 REMARK 465 LEU A 210 REMARK 465 GLU A 211 REMARK 465 HIS A 212 REMARK 465 HIS A 213 REMARK 465 HIS A 214 REMARK 465 HIS A 215 REMARK 465 HIS A 216 REMARK 465 HIS A 217 REMARK 465 MET B 1 REMARK 465 SER B 73 REMARK 465 ALA B 74 REMARK 465 SER B 75 REMARK 465 GLY B 76 REMARK 465 GLY B 77 REMARK 465 GLY B 78 REMARK 465 GLY B 79 REMARK 465 GLY B 80 REMARK 465 GLY B 81 REMARK 465 ASN B 197 REMARK 465 ASN B 198 REMARK 465 ALA B 199 REMARK 465 ALA B 200 REMARK 465 ALA B 201 REMARK 465 GLU B 202 REMARK 465 SER B 203 REMARK 465 ARG B 204 REMARK 465 LYS B 205 REMARK 465 GLY B 206 REMARK 465 GLN B 207 REMARK 465 GLU B 208 REMARK 465 ARG B 209 REMARK 465 LEU B 210 REMARK 465 GLU B 211 REMARK 465 HIS B 212 REMARK 465 HIS B 213 REMARK 465 HIS B 214 REMARK 465 HIS B 215 REMARK 465 HIS B 216 REMARK 465 HIS B 217 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 MET A 159 55.21 -109.98 REMARK 500 MET B 159 55.44 -109.14 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 3CQ A 301 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 3CQ B 301 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 4TUH RELATED DB: PDB REMARK 999 REMARK 999 SEQUENCE REMARK 999 PROTEIN CONSTRUCT COMPRISES UNP RESIDUES 1-23 AND 83-209 CONNECTED REMARK 999 BY AN ASGGGGGGG LINKER. DBREF 4QVX A 1 73 UNP Q07817 B2CL1_HUMAN 1 23 DBREF 4QVX A 83 209 UNP Q07817 B2CL1_HUMAN 83 209 DBREF 4QVX B 1 73 UNP Q07817 B2CL1_HUMAN 1 23 DBREF 4QVX B 83 209 UNP Q07817 B2CL1_HUMAN 83 209 SEQADV 4QVX ALA A 74 UNP Q07817 LINKER SEQADV 4QVX SER A 75 UNP Q07817 LINKER SEQADV 4QVX GLY A 76 UNP Q07817 LINKER SEQADV 4QVX GLY A 77 UNP Q07817 LINKER SEQADV 4QVX GLY A 78 UNP Q07817 LINKER SEQADV 4QVX GLY A 79 UNP Q07817 LINKER SEQADV 4QVX GLY A 80 UNP Q07817 LINKER SEQADV 4QVX GLY A 81 UNP Q07817 LINKER SEQADV 4QVX GLY A 82 UNP Q07817 LINKER SEQADV 4QVX LYS A 158 UNP Q07817 GLU 158 CONFLICT SEQADV 4QVX ALA A 189 UNP Q07817 ASP 189 CONFLICT SEQADV 4QVX LEU A 210 UNP Q07817 EXPRESSION TAG SEQADV 4QVX GLU A 211 UNP Q07817 EXPRESSION TAG SEQADV 4QVX HIS A 212 UNP Q07817 EXPRESSION TAG SEQADV 4QVX HIS A 213 UNP Q07817 EXPRESSION TAG SEQADV 4QVX HIS A 214 UNP Q07817 EXPRESSION TAG SEQADV 4QVX HIS A 215 UNP Q07817 EXPRESSION TAG SEQADV 4QVX HIS A 216 UNP Q07817 EXPRESSION TAG SEQADV 4QVX HIS A 217 UNP Q07817 EXPRESSION TAG SEQADV 4QVX ALA B 74 UNP Q07817 LINKER SEQADV 4QVX SER B 75 UNP Q07817 LINKER SEQADV 4QVX GLY B 76 UNP Q07817 LINKER SEQADV 4QVX GLY B 77 UNP Q07817 LINKER SEQADV 4QVX GLY B 78 UNP Q07817 LINKER SEQADV 4QVX GLY B 79 UNP Q07817 LINKER SEQADV 4QVX GLY B 80 UNP Q07817 LINKER SEQADV 4QVX GLY B 81 UNP Q07817 LINKER SEQADV 4QVX GLY B 82 UNP Q07817 LINKER SEQADV 4QVX LYS B 158 UNP Q07817 GLU 158 CONFLICT SEQADV 4QVX ALA B 189 UNP Q07817 ASP 189 CONFLICT SEQADV 4QVX LEU B 210 UNP Q07817 EXPRESSION TAG SEQADV 4QVX GLU B 211 UNP Q07817 EXPRESSION TAG SEQADV 4QVX HIS B 212 UNP Q07817 EXPRESSION TAG SEQADV 4QVX HIS B 213 UNP Q07817 EXPRESSION TAG SEQADV 4QVX HIS B 214 UNP Q07817 EXPRESSION TAG SEQADV 4QVX HIS B 215 UNP Q07817 EXPRESSION TAG SEQADV 4QVX HIS B 216 UNP Q07817 EXPRESSION TAG SEQADV 4QVX HIS B 217 UNP Q07817 EXPRESSION TAG SEQRES 1 A 167 MET SER GLN SER ASN ARG GLU LEU VAL VAL ASP PHE LEU SEQRES 2 A 167 SER TYR LYS LEU SER GLN LYS GLY TYR SER ALA SER GLY SEQRES 3 A 167 GLY GLY GLY GLY GLY GLY MET ALA ALA VAL LYS GLN ALA SEQRES 4 A 167 LEU ARG GLU ALA GLY ASP GLU PHE GLU LEU ARG TYR ARG SEQRES 5 A 167 ARG ALA PHE SER ASP LEU THR SER GLN LEU HIS ILE THR SEQRES 6 A 167 PRO GLY THR ALA TYR GLN SER PHE GLU GLN VAL VAL ASN SEQRES 7 A 167 GLU LEU PHE ARG ASP GLY VAL ASN TRP GLY ARG ILE VAL SEQRES 8 A 167 ALA PHE PHE SER PHE GLY GLY ALA LEU CYS VAL GLU SER SEQRES 9 A 167 VAL ASP LYS LYS MET GLN VAL LEU VAL SER ARG ILE ALA SEQRES 10 A 167 ALA TRP MET ALA THR TYR LEU ASN ASP HIS LEU GLU PRO SEQRES 11 A 167 TRP ILE GLN GLU ASN GLY GLY TRP ALA THR PHE VAL GLU SEQRES 12 A 167 LEU TYR GLY ASN ASN ALA ALA ALA GLU SER ARG LYS GLY SEQRES 13 A 167 GLN GLU ARG LEU GLU HIS HIS HIS HIS HIS HIS SEQRES 1 B 167 MET SER GLN SER ASN ARG GLU LEU VAL VAL ASP PHE LEU SEQRES 2 B 167 SER TYR LYS LEU SER GLN LYS GLY TYR SER ALA SER GLY SEQRES 3 B 167 GLY GLY GLY GLY GLY GLY MET ALA ALA VAL LYS GLN ALA SEQRES 4 B 167 LEU ARG GLU ALA GLY ASP GLU PHE GLU LEU ARG TYR ARG SEQRES 5 B 167 ARG ALA PHE SER ASP LEU THR SER GLN LEU HIS ILE THR SEQRES 6 B 167 PRO GLY THR ALA TYR GLN SER PHE GLU GLN VAL VAL ASN SEQRES 7 B 167 GLU LEU PHE ARG ASP GLY VAL ASN TRP GLY ARG ILE VAL SEQRES 8 B 167 ALA PHE PHE SER PHE GLY GLY ALA LEU CYS VAL GLU SER SEQRES 9 B 167 VAL ASP LYS LYS MET GLN VAL LEU VAL SER ARG ILE ALA SEQRES 10 B 167 ALA TRP MET ALA THR TYR LEU ASN ASP HIS LEU GLU PRO SEQRES 11 B 167 TRP ILE GLN GLU ASN GLY GLY TRP ALA THR PHE VAL GLU SEQRES 12 B 167 LEU TYR GLY ASN ASN ALA ALA ALA GLU SER ARG LYS GLY SEQRES 13 B 167 GLN GLU ARG LEU GLU HIS HIS HIS HIS HIS HIS HET 3CQ A 301 47 HET 3CQ B 301 47 HETNAM 3CQ 2-[8-(1,3-BENZOTHIAZOL-2-YLCARBAMOYL)-3,4- HETNAM 2 3CQ DIHYDROISOQUINOLIN-2(1H)-YL]-5-(3-{4-[3- HETNAM 3 3CQ (DIMETHYLAMINO)PROP-1-YN-1-YL]-2- HETNAM 4 3CQ FLUOROPHENOXY}PROPYL)-1,3-THIAZOLE-4-CARBOXYLIC ACID FORMUL 3 3CQ 2(C35 H32 F N5 O4 S2) FORMUL 5 HOH *153(H2 O) HELIX 1 1 SER A 2 LYS A 20 1 19 HELIX 2 2 MET A 83 TYR A 101 1 19 HELIX 3 3 ARG A 102 PHE A 105 5 4 HELIX 4 4 LEU A 108 HIS A 113 1 6 HELIX 5 5 ALA A 119 PHE A 131 1 13 HELIX 6 6 ASN A 136 LYS A 157 1 22 HELIX 7 7 VAL A 161 LEU A 178 1 18 HELIX 8 8 LEU A 178 ASN A 185 1 8 HELIX 9 9 GLY A 186 GLY A 196 1 11 HELIX 10 10 GLN B 3 LYS B 20 1 18 HELIX 11 11 MET B 83 TYR B 101 1 19 HELIX 12 12 ARG B 102 PHE B 105 5 4 HELIX 13 13 LEU B 108 HIS B 113 1 6 HELIX 14 14 ALA B 119 PHE B 131 1 13 HELIX 15 15 ASN B 136 LYS B 157 1 22 HELIX 16 16 VAL B 161 LEU B 178 1 18 HELIX 17 17 LEU B 178 ASN B 185 1 8 HELIX 18 18 GLY B 187 GLY B 196 1 10 SITE 1 AC1 21 ALA A 93 GLU A 96 PHE A 97 TYR A 101 SITE 2 AC1 21 ARG A 102 PHE A 105 SER A 106 ASP A 107 SITE 3 AC1 21 LEU A 108 LEU A 130 ASP A 133 ASN A 136 SITE 4 AC1 21 GLY A 138 ARG A 139 VAL A 141 ALA A 142 SITE 5 AC1 21 SER A 145 PHE A 146 TYR A 195 HOH A 407 SITE 6 AC1 21 HOH A 420 SITE 1 AC2 23 ALA B 93 GLU B 96 PHE B 97 TYR B 101 SITE 2 AC2 23 ARG B 102 PHE B 105 SER B 106 ASP B 107 SITE 3 AC2 23 LEU B 108 THR B 109 LEU B 130 ARG B 132 SITE 4 AC2 23 ASN B 136 GLY B 138 ARG B 139 VAL B 141 SITE 5 AC2 23 ALA B 142 SER B 145 PHE B 146 ALA B 149 SITE 6 AC2 23 TYR B 195 HOH B 405 HOH B 434 CRYST1 73.107 90.955 83.736 90.00 90.00 90.00 C 2 2 21 16 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.013679 0.000000 0.000000 0.00000 SCALE2 0.000000 0.010994 0.000000 0.00000 SCALE3 0.000000 0.000000 0.011942 0.00000